Skip to main content
Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
455.48
-1.88 (-0.41%)
At close: Dec 5, 2025, 4:00 PM EST
455.97
+0.49 (0.11%)
After-hours: Dec 5, 2025, 7:46 PM EST

Vertex Pharmaceuticals Revenue By Geography
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
United States
7.29B 7.03B 6.82B 6.68B 6.42B 6.26B 6.16B 6.04B
United States Growth
13.58% 12.27% 10.75% 10.67% 8.37% 7.47% 7.35% 5.98%
Europe
3.41B 3.42B 3.31B 3.45B 3.36B 3.28B 3.27B 3.11B
Europe Growth
1.47% 4.31% 1.34% 11.09% 9.68% 8.30% 13.50% 14.91%
Other
991.70M 939.20M 958.10M 881.30M 846.30M 798.40M 759.30M 719.80M
Other Growth
17.18% 17.64% 26.18% 22.44% 26.86% 22.36% 28.11% 36.87%

Revenue By Segment
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Trikafta and Kaftrio
10.46B 10.39B 10.29B 10.19B 9.81B 9.50B 9.29B 8.94B - - -
Trikafta and Kaftrio Growth
6.67% 9.44% 10.80% 13.95% 13.59% 13.46% 15.77% 16.36% - - -
Kalydeco
- - - - - - - 475.50M 499.20M 525.80M 539.20M 553.20M 569.30M 592.30M 636.90M
Kalydeco Growth
- - - - - - - -14.05% -12.31% -11.23% -15.34% -19.15% -21.52% -21.74% -17.99%
Orkambi
- - - - - - - 326.00M 392.60M 475.80M 501.10M 510.70M 547.30M 585.60M 685.00M
Orkambi Growth
- - - - - - - -36.17% -28.27% -18.75% -26.85% -33.81% -34.82% -33.54% -23.21%
Symdeko and Semkevi
- - - - - - - 123.00M 129.50M 134.30M 145.80M 180.00M 226.10M 269.30M 360.10M
Symdeko and Semkevi Growth
- - - - - - - -31.67% -42.72% -50.13% -59.51% -57.18% -51.64% -50.34% -37.97%

Operating Expense Breakdown
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019
Research and Development
3.93B 3.83B 3.82B 3.63B 3.46B 3.39B 3.21B 3.16B
Research and Development Growth
13.84% 13.05% 19.05% 14.78% 13.98% 18.24% 19.67% 24.51%
Selling, General, and Administrative
1.64B 1.57B 1.52B 1.46B 1.46B 1.35B 1.24B 1.14B
Selling, General, and Administrative Growth
12.91% 16.52% 22.60% 28.83% 40.67% 32.41% 27.57% 20.31%
Acquired In-Process Research and Development
164.00M 124.50M 4.57B 4.63B 4.56B 4.60B 256.80M 527.10M - - - - - - - - -
Acquired In-Process Research and Development Growth
-96.40% -97.29% 1,680.14% 778.09% 757.06% 802.47% -44.25% 356.36% - - - - - - - - -
Change in Value of Contingent Consideration
- 2.20M 1.80M -500.00K -49.60M -48.70M -49.80M -51.60M - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.